NOVEL OLIGOSACCHARIDES FOR USE IN PREBIOTIC APPLICATIONS
Mare's milk plays a major role in the health of neonatal foals and may be used for human or other mammalian health. Oligosaccharides (OS) possess various bioactivities in many mammalian milks, and Mare's milk may be a source of novel oligosaccharides. The invention relates to the identification of novel structures in mare's milk that may be synthesized or otherwise purified for use in a variety of animal and human applications related to the gut microbiome and mammalian health.
1 . A composition comprising an oligosaccharide selected from at least one of 2Hex, 2HexNAc; 2Hex, 1HexNAc 1Neu5Ac; 2Hex, 1HexNAc 1Neu5Ac; 5Hex 1Neu5Ac; 2Hex 2HexNAc 1 Neu5Ac; 2Hex 2HexNAc 1 Neu5Ac; 1Hex 1HexNAc 1 Fuc; Gal(β1-3)Gal(β1-4)Glc; Gal(β1-6)Gal(β1-4)Glc; Gal(β1-3)[Gal(β1-4)GlcNAc(β1-6)]Gal(β1-4)Glc.
2 . The composition of claim 1 further comprising at least one bacterial species selected from Bifidobacterium, Lactobacillus or Pedicoccus.
3 . A composition of claim 2 wherein the Bifidobacterium species may be selected from Bifidobacterium adolescentis, Bifidobacterium animalis , (e.g., Bifidobacterium animalis subsp. animalis, Bifidobacterium animalis subsp. lactis), Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium catenulatum, Bifidobacterium longum (e.g., Bifidobacterium longum subsp. suis, Bifidobacterium longum subsp. infantis ( B. infantis ) or Bifidobacterium longum subsp. longum), Bifidobacterium pseudocatanulatum, Bifidobacterium pseudolongum , or wherein the Lactobacillus species is selected from Lactobacillus acidophilus, Lactobacillus antri, Lactobacillus brevis, Lactobacillus casei, Lactobacillus coleohominis, Lactobacillus crispatus, Lactobacillus curvatus, Lactobacillus fermentum, Lactobacillus gasseri, Lactobacillus johnsonii, Lactobacillus mucosae, Lactobacillus pentosus, Lactobacillus plantarum, Lactobacillus reuteri, Lactobacillus rhamnosus, Lactobacillus sakei, Lactobacillus salivarius, Lactobacillus paracasei, Lactobacillus kisonensis., Lactobacillus paralimentarius, Lactobacillus perolens, Lactobacillus apis, Lactobacillus ghanensis, Lactobacillus dextrinicus, Lactobacillus shenzenensis, Lactobacillus harbinensis, Lactobacillus equi , or wherein the Pediococcus is selected from Pediococcus parvulus, Pediococcus lolii, Pediococcus acidilactici, Pediococcus argentinicus, Pediococcus claussenii, Pediococcus pentosaceus, or Pediococcus stilesii.
4 . (canceled)
5 . The composition of claim 1 , wherein the B. infantis is activated.
6 - 9 . (canceled)
10 . The composition of claim 1 further comprising an oligosaccharides selected from lacto-N-biose (LNB), N-acetyl lactosamine, lacto-N-triose, lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), fucosyllactose (FL), lacto-N-fucopentaose (LNFP),lactodifucotetraose, (LDFT) sialyllactose (SL), disialyllacto-N-tetraose (DSLNT), 2′-fucosyllactose (2FL), 3′-sialyllactosamine (3SLN), 3′-fucosyllactose (3FL), 3′-sialyl-3-fucosyllactose(3S3FL), 3′-sialyllactose (3SL), 6′-sialyllactosamine (6SLN), 6′-sialyllactose (6SL), difucosyllactose (DFL), lacto-N-fucopentaose I (LNFPI), lacto-N-fucopentaose II (LNFPII), lacto-N-fucopentaose III (LNFPIII), lacto-N-fucopentaose V (LNFPV), sialyllacto-N-tetraose (SLNT), their derivatives, or combinations thereof
11 . A composition of claim 10 wherein the oligosaccharides may include: (a) include one or more Type II oligosaccharide core where representative species include LNnT; (b) one or more oligosaccharides containing the Type II core and GOS, FOS or XOS in 1:5 to 5:1 ratio; (c) one or more oligosaccharides containing the Type II core and 2FL in 1:5 to 5:1 ratio; (d) a combination of (a), (b), and/or (c); (e) include one or more Type I oligosaccharide core where representative species include LNT (f) one or more Type I core and GOS in 1:5 to 5:1 ratio; (g) one or more Type I core and 2FL in 1:5 to 5:1 ratio; and/or (h) a combination of any of (a) to (g) that includes both a type I and type II core.
12 . The composition of claim 1 wherein the composition is a nutritional composition.
13 . A method of promoting mammalian health comprising administering a composition comprising 2Hex, 2HexNAc; 2Hex, 1HexNAc 1Neu5Ac; 2Hex, 1HexNAc 1Neu5Ac; 5Hex 1Neu5Ac; 2Hex 2HexNAc 1 Neu5Ac; 2Hex 2HexNAc 1 Neu5Ac; 1Hex 1HexNAc 1 Fuc Gal(β1-3)Gal(β1-4)Glc, Gal(β1-6)Gal(β1-4)Glc and/or Gal(β1-3)[Gal(β1-4)GlcNAc(β1-6)]Gal(β1-4)Glc to a mammal.
14 . A method of claim 13 further comprising administering at least one bacterial species selected from Bifidobacterium, Lactobacillus or Pedicoccus to the mammal.
15 . The method of claim 14 wherein the administered Bifidobacterium species may be selected from Bifidobacterium adolescentis, Bifidobacterium animalis , (e.g., Bifidobacterium animalis subsp. animalis, Bifidobacterium animalis subsp. lactis), Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium catenulatum, Bifidobacterium longum (e.g., Bifidobacterium longum subsp. suis, Bifidobacterium longum subsp. infantis ( B. infantis ) or Bifidobacterium longum subsp. longum), Bifidobacterium pseudocatanulatum, Bifidobacterium pseudolongum , or wherein the administered Lactobacillus species is selected from Lactobacillus acidophilus, Lactobacillus antri, Lactobacillus brevis, Lactobacillus casei, Lactobacillus coleohominis, Lactobacillus crispatus, Lactobacillus curvatus, Lactobacillus fermentum, Lactobacillus gasseri, Lactobacillus johnsonii, Lactobacillus mucosae, Lactobacillus pentosus, Lactobacillus plantarum, Lactobacillus reuteri, Lactobacillus rhamnosus, Lactobacillus sakei, Lactobacillus salivarius, Lactobacillus paracasei, Lactobacillus kisonensis ., Lactobacillus paralimentarius, Lactobacillus perolens, Lactobacillus apis, Lactobacillus ghanensis, Lactobacillus dextrinicus, Lactobacillus shenzenensis, Lactobacillus harbinensis, Lactobacillus equi , or wherein the administered Pediococcus is selected from Pediococcus parvulus, Pediococcus lolii, Pediococcus acidilactici, Pediococcus argentinicus, Pediococcus claussenii, Pediococcus pentosaceus , or Pediococcus stilesii.
16 . (canceled)
17 . A method of claim 14 , wherein the B. infantis is activated.
18 .- 21 . (canceled)
22 . The method of claim 13 , wherein the composition administered further comprises an oligosaccharides selected from lacto-N-biose (LNB), N-acetyl lactosamine, lacto-N-triose, lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), fucosyllactose (FL), lacto-N-fucopentaose (LNFP), lactodifucotetraose, (LDFT) sialyllactose (SL), disialyllacto-N-tetraose (DSLNT), 2′-fucosyllactose (2FL), 3′-sialyllactosamine (3SLN), 3′-fucosyllactose (3FL), 3′-sialyl-3-fucosyllactose(3S3FL), 3′-sialyllactose (3SL), 6′-sialyllactosamine (6SLN), 6′-sialyllactose (6SL), difucosyllactose (DFL), lacto-N-fucopentaose I (LNFPI), lacto-N-fucopentaose II (LNFPII), lacto-N-fucopentaose III (LNFPIII), lacto-N-fucopentaose V (LNFPV), sialyllacto-N-tetraose (SLNT), their derivatives, or combinations thereof.
23 . The method of claim 13 , wherein the oligosaccharides may include: (a) include one or more Type II oligosaccharide core where representative species include LNnT; (b) one or more oligosaccharides containing the Type II core and GOS in 1:5 to 5:1 ratio; (c) one or more oligosaccharides containing the Type II core and 2FL in 1:5 to 5:1 ratio; (d) a combination of (a), (b), and/or (c); (e) include one or more Type I oligosaccharide core where representative species include LNT (f) one or more Type I core and GOS in 1:5 to 5:1 ratio; (g) one or more Type I core and 2FL in 1:5 to 5:1 ratio; and/or (h) a combination of any of (a) to (g) that includes both a type I and type II core.
24 . The method of claim 13 , further comprising administering to the mammal a nutritive composition for mammalian neonates, comprising milk oligosaccharides found in (a) mammalian milk, preferably in equine, human or bovine milk, and/or (b) equine milk and optionally (c) a bacteria.
25 . The method of claim 24 , wherein the milk oligosaccharides are provided by inclusion in the nutritive composition one or more of human milk, bovine milk, infant formula, follow on formula, weaning foods, baby foods, meal replacers, feeds and feed supplements, beverages, post-surgery recovery drinks, in a powder form, which may optionally be suspended in oil, to be added to conventional foods or beverages.
26 . The method of claim 13 , wherein the administered composition is used increase the abundance of Bifidobacterium in the intestine of the mammal.
27 . A method of claim 26 , wherein the composition further reduces the abundance of pathogens in the intestines of the mammal.
28 . A method of claim 26 , wherein the composition reduces stool pH.
29 . A method of claim 26 , wherein the composition reduces inflammation in the mammal.
30 . A method of claim 26 , wherein the composition is used to reduce symptoms of autoimmune diseases in the mammal.